Tenax Therapeutics, Inc. (NASDAQ:TENX)
| Market Cap | 51.06M-70.7% |
| Revenue (ttm) | 0 |
| Net Income | -64.86M-106.0% |
| EPS | -1.49-62.0% |
| Shares Out | 26.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,980,523.468 |
| Open | 1.91 |
| Previous Close | 1.94 |
| Day's Range | 1.85 - 1.94 |
| 52-Week Range | 1.31 - 19.40 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 4.40(+128.57%) |
| Earnings Date | Nov 11, 2026 |
TENAX THERAPEUTICS, INC. has a live Insider Score.
Scored on 3 qualifying trades from 2 insiders in the last 90 days.
About TENX
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TENX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TENX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TENX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TENX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TENX Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TENX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TENX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TENX
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $1.68M |
| VTIVanguard Morningstar Total Stock Market ETF | $1.57M |
| VXFVanguard Extended Market ETF | $514.67K |
| VTWOVanguard Russell 2000 ETF | $265.34K |
| IWCiShares Micro-Cap ETF | $224.61K |
| FESMFidelity Enhanced Small Cap ETF | $116.81K |
Estimated from each fund’s disclosed top holdings × AUM
TENX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TENX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score